Michael Freeman
Stock Analyst at Raymond James
(3.01)
# 1,318
Out of 5,112 analysts
6
Total ratings
80%
Success rate
66.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $15.54 | -9.91% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $18.37 | +313.72% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $18.55 | +99.46% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $90.44 | -1.59% | 1 | Jun 11, 2025 | |
| RNA Avidity Biosciences | Initiates: Strong Buy | $65 | $72.14 | -9.89% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $6.82 | +17.30% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $15.54
Upside: -9.91%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $18.37
Upside: +313.72%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $18.55
Upside: +99.46%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $90.44
Upside: -1.59%
Avidity Biosciences
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $72.14
Upside: -9.89%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $6.82
Upside: +17.30%